34,139 Shares in Guardant Health, Inc. $GH Bought by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 34,139 shares of the company’s stock, valued at approximately $6,089,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. First Pacific Financial increased its position in Guardant Health by 14.7% during the third quarter. First Pacific Financial now owns 1,522 shares of the company’s stock worth $271,000 after buying an additional 195 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Guardant Health by 70.9% in the third quarter. GAMMA Investing LLC now owns 1,649 shares of the company’s stock valued at $294,000 after buying an additional 684 shares during the last quarter. Green Alpha Advisors LLC raised its holdings in Guardant Health by 19.6% in the 3rd quarter. Green Alpha Advisors LLC now owns 3,073 shares of the company’s stock valued at $548,000 after acquiring an additional 504 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Guardant Health by 87.9% during the third quarter. Farther Finance Advisors LLC now owns 2,255 shares of the company’s stock worth $402,000 after buying an additional 1,055 shares during the period. Finally, Whalen Wealth Management Inc. purchased a new position in shares of Guardant Health during the 3rd quarter worth about $275,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In related news, Director Ian Clark sold 14,180 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the completion of the sale, the director directly owned 2,975 shares of the company’s stock, valued at approximately $472,787. This represents a 82.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terilyn Monroe sold 46,300 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the sale, the insider directly owned 22,979 shares of the company’s stock, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 178,824 shares of company stock worth $30,051,669. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Stock Up 1.8%

GH opened at $165.88 on Friday. Guardant Health, Inc. has a 52-week low of $64.00 and a 52-week high of $191.05. The company has a 50 day moving average of $168.14 and a two-hundred day moving average of $139.02. The company has a market cap of $22.26 billion, a P/E ratio of -47.53 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same period in the previous year, the company earned ($0.44) EPS. Guardant Health’s revenue was up 44.3% on a year-over-year basis. Research analysts anticipate that Guardant Health, Inc. will post -3.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GH has been the topic of several research reports. Citigroup increased their target price on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Barclays boosted their price target on Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada upped their price target on Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Canaccord Genuity Group raised their price objective on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, Bank of America raised their price objective on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $190.00.

Guardant Health Profile

Guardant Health, Inc (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor’s molecular characteristics.

The company’s products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment.